From 2012.igem.org

Revision as of 21:20, 26 September 2012

• Home
• Team
  • The Team
  • Team Registration
• Project
  • 1. Introduction
  • 2. PnA System
  • 3. Virus-Like Particles
    • CCMV
    • HepB
    • Polerovirus Natural BioBrick
  • 4. Outside Modification
  • 5. Inside Modification
  • 6. Detection of VLPs
  • 7. Applications
  • 8. The Constructor
  • 9. Final Overview
• Human Practices
  • Human Practices Home
  • 1. Mini Symposium
  • 2. Visiting Secondary Schools
  • 3. Discovery Festival
    • Communication Science
  • 4. Stakeholders
  • 5. Munich CAS Conference
• Safety
  • Introduction
  • 1. General safety
  • 2. Virus-related safety
  • 3. Regulations
  • 4. Safety suggestions
  • 5. Safety of applications
• Modeling
  • Human Body Model
  • Tertiary folding prediction
  • VLP assembly model
• Attributions
• Parts
• Notebook
  • Journal
  • Protocols

---

Last year's project: Synchronized Oscillatory System

iGEM Home

Contact Us

Our Sponsors:

Introduction

The Wageningen UR team has worked on the modification of virus-like particles (VLPs) to make them interesting platforms for vaccine production and/or site specific drug delivery. VLPs are empty virus capsids, meaning that they do not contain any viral genome and proteins except for the coat proteins. Coat proteins of some viruses have shown the ability to self-assemble in absence of its viral genome and other viral proteins, and thus form VLPs.

Besides the work done in the wet lab on VLPs, the team developed a web based tool that simplifies the design of the best cloning strategy: The Constructor. The team cooperated with the 2011 Wageningen UR iGEM team for this purpose. Their experiences were used to further develop the tool adding features and making a user-friendly and easily accessible tool. This work has already been published.

The Virus-Like Particle project

To facilitate the attachment of ligands and epitopes, we want to attach anchors on the outside and inside of the VLP. Medicine can be attached to the anchors inside the VLP, which then is encapsulated inside the VLP. The anchors that we want to use are charged coils, which are already being used to encapsulate GFP into Cowpea Chlorotic Mottle Virus (CCMV) VLPs. This technique relies on charged peptide coils (negatively charged E-coil and positively charged K-coil) that can form ion bonds together. We want to use this technique to obtain a universal attachment system with which we can attach all kinds of epitopes to the VLPs. We selected 3 viruses that we want to use to produce VLPs with a universal attachment system on the inside and outside of the VLPs. We have selected them based on the availability of literature that describes the characteristics of the VLPs, increasing the probability of success and their promising structure. Besides CCMV, we will use the Hepatitis B core antigen VLP for the production of vaccines. The Polerovirus (PLRV) will be used to yield a newly expressed VLP in Escherichia coli (E.coli), because of its promising structure with outside spikes that are easy to modify. All three VLPs will be expressed in E. coli and all three will need to be submitted in the same standardized form for the iGEM competition. Formation of VLPs is usually confirmed using Electron Microscopy (EM). This is rather time consuming and expensive, so Dynamic Light Scattering (DLS) is investigated as an alternative method. DLS can provide an indication of VLP formation but conclusive evidence should be obtained by EM.
VLPs can have many applications in the health industry, but they can also find their way in the development of bio-nano materials and processing engineering.